CFTR Activator Compounds for Consistent Constipation and Dry Eye Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for constipation and dry eye disorders are inadequate, with limited efficacy and a need for safer and more effective therapeutic options.
Innovation Solution
Development of compounds that activate the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) to treat constipation, dry eye disorders, and other diseases by administering effective amounts of specific compounds to subjects in need.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current laxatives and chloride channel activators are used to treat constipation, then some therapeutic effect is achieved, but efficacy is variable and unimpressive
Solution Approach 1:
The patent modifies the chemical structure of known CFTR activators by introducing specific substituents at the R1 position (including cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl groups and their substituted variants) to optimize pharmacological properties. These structural parameter changes aim to improve therapeutic efficacy and consistency while maintaining the core mechanism of CFTR channel activation for treating constipation
2Reliability
If topical cyclosporine is used to treat dry eye, then ocular surface inflammation is reduced, but symptoms are not eliminated in most patients
Solution Approach 1:
The patent applies structural modifications to CFTR activator compounds, specifically incorporating cycloalkyl and heterocycloalkyl groups at the R1 position to enhance pharmacological activity. These parameter changes are designed to improve tear secretion stimulation and ocular surface hydration, providing more effective symptom relief for dry eye patients compared to existing anti-inflammatory treatments
3Adaptability or versatility
If multiple therapeutic options are available for constipation, then treatment choices are increased, but safety and effectiveness remain insufficient
Solution Approach 1:
The patent introduces specific local structural features (cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl groups and their substituted variants) at the R1 position of the CFTR activator molecule. These localized structural modifications are designed to enhance compound stability, selectivity, and pharmacokinetic properties, thereby improving both safety and effectiveness while maintaining the diversity of therapeutic options
Solution Approach 2:
The patent creates composite molecular structures by combining the core CFTR activator scaffold with various cycloalkyl and heterocycloalkyl substituents. These composite structures integrate multiple functional groups to achieve optimized pharmacological profiles, providing safer and more effective treatment options for constipation and dry eye disorders
Data Source
AI summary
Provided herein are compounds that activate CFTR and methods for treating constipation, dry eye disorders, and other diseases and disorders.